March 08, 2026 — Waltham, Massachusetts, USA
Clinical-stage biotechnology innovator Dyne Therapeutics has announced the initiation of the Phase 3 HARMONIA clinical trial evaluating z-basivarsen (DYNE-101) for the treatment of Myotonic Dystrophy Type 1 (DM1), a rare and progressive genetic disease affecting thousands of patients worldwide. The global trial will assess the efficacy, safety, and tolerability of the investigational therapy in approximately 150 participants, marking a major milestone in the development of a potential disease-modifying treatment for DM1. The Phase 3 program reflects growing momentum in neuromuscular research and underscores Dyne Therapeutics’ commitment to advancing targeted therapies that address the underlying genetic causes of debilitating muscle disorders.
Global Phase 3 Trial Designed to Demonstrate Functional Benefits
The HARMONIA study is a randomized, placebo-controlled, double-blind Phase 3 clinical trial designed to evaluate the clinical impact of z-basivarsen administered intravenously in individuals aged 16 and older living with myotonic dystrophy type 1. Participants enrolled in the study will receive either 6.8 mg/kg of z-basivarsen or placebo once every eight weeks over a 48-week treatment period, followed by an optional 24-week extension phase during which all participants may receive active treatment. The study design was developed in collaboration with the U.S. Food and Drug Administration (FDA) and is intended to serve as a confirmatory trial supporting potential regulatory approval in the United States and international markets.
The trial’s primary endpoint will measure the change from baseline in the five times sit-to-stand (5xSTS) test at week 49, a validated functional measure reflecting lower-body strength, balance, and trunk stability—key factors influencing mobility and daily functioning in patients with DM1. Secondary endpoints include video hand opening time, quantitative muscle testing, the 10-Meter Walk/Run test, and patient-reported outcomes, enabling researchers to assess improvements across multiple dimensions of disease burden. Additional exploratory endpoints will evaluate central nervous system (CNS) involvement, an important aspect of the disease that contributes to fatigue, cognitive impairment, and other neurological symptoms.
Innovative Antisense Therapy Targets the Root Cause of DM1
Advertisement
Z-basivarsen represents a next-generation antisense oligonucleotide (ASO) therapy designed to address the genetic mechanisms responsible for myotonic dystrophy type 1. The therapy combines an antisense molecule with an antigen-binding fragment that targets transferrin receptor 1, enabling efficient delivery to both muscle tissue and the central nervous system. This targeted delivery approach is designed to reduce toxic DMPK RNA molecules, which accumulate in DM1 patients and disrupt normal RNA splicing processes essential for healthy muscle and neurological function.
By reducing these toxic RNA transcripts, z-basivarsen aims to restore normal cellular protein production and improve functional outcomes for patients, potentially addressing the root cause of disease rather than only managing symptoms. The investigational therapy has already received several important regulatory recognitions, including Breakthrough Therapy, Fast Track, and Orphan Drug designations from the U.S. FDA, as well as Orphan Drug designation from the European Medicines Agency and Japan’s Ministry of Health, Labour and Welfare. These designations highlight the significant unmet medical need for effective DM1 therapies and the potential clinical impact of this novel treatment approach.
Addressing a Major Unmet Need in Rare Neuromuscular Disease
Myotonic dystrophy type 1 is a rare, progressive neuromuscular disorder caused by mutations in the DMPK gene, leading to widespread disruptions in RNA splicing and affecting multiple organ systems throughout the body. Patients with DM1 experience a broad range of symptoms including muscle weakness, myotonia (difficulty relaxing muscles), fatigue, cognitive impairment, cardiac arrhythmias, respiratory complications, and gastrointestinal dysfunction. The disease affects approximately 40,000 individuals in the United States and around 55,000 in Europe, yet there are currently no approved disease-modifying treatments capable of addressing its underlying genetic cause.
Through the initiation of the HARMONIA trial, Dyne Therapeutics aims to generate robust clinical evidence supporting z-basivarsen as a potential first-in-class treatment for DM1, capable of delivering meaningful improvements in muscle function and overall quality of life. If successful, the trial could mark a pivotal step toward bringing the first targeted genetic therapy for myotonic dystrophy to patients worldwide, reinforcing the growing role of precision biotechnology in treating rare genetic diseases.
As the field of neuromuscular medicine continues to evolve, clinical programs like HARMONIA demonstrate how innovative RNA-targeting therapies and advanced drug delivery technologies are transforming the landscape of rare disease treatment. By targeting the molecular drivers of disease and restoring normal cellular function, next-generation therapies such as z-basivarsen have the potential to redefine therapeutic possibilities for patients living with debilitating genetic disorders.
z
Source: Dyne Therapeutics press release
